← FDA DRUG APPROVALS

FDA ANDA · ANDA214623

CARDIOPLEGIC SOLUTION

potassium chloride, sodium chloride, calcium chloride, and magnesium chloride

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA214623
TYPE
ANDA
ORIGINAL APPROVAL
2022-02-18
LATEST ACTION
2022-02-18
ROUTE
INTRA-ARTERIAL, PERFUSION, CARDIAC
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

CARDIOPLEGIC IN PLASTIC CONTAINERPrescription
CALCIUM CHLORIDE 17.6MG/100ML, MAGNESIUM CHLORIDE 325.3MG/100ML, POTASSIUM CHLORIDE 119.3MG/100ML, SODIUM CHLORIDE 643MG/100ML · SOLUTION · PERFUSION, CARDIAC

Approval history

2022-02-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →